Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 226 followers
Latest posts
Last updated 5 days ago
Lilly announces changes on board of directors
5 days ago
INDIANAPOLIS , Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
6 days ago
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel...
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
8 days ago
In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical...
Lilly Statement on New 340B Litigation
10 days ago
Today, Lilly sued HRSA over its purported rejection of Lilly’s plan to...
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
11 days ago
SURMOUNT-1 results show a 94% reduction in risk of progression to type...
Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
19 days ago
INDIANAPOLIS , Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
23 days ago
INDIANAPOLIS , Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
25 days ago
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
26 days ago
A change in the initiation of donanemab dosing, shifting one vial of...
Lilly declares fourth-quarter 2024 dividend
27 days ago
INDIANAPOLIS , Oct. 28, 2024 /PRNewswire/ -- The board of directors of...
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
27 days ago
At three years, over 80% of patients with moderately to severely active...
Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab
about 1 month ago
In first dedicated study of a selective IL-13 inhibitor in patients previously...